PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.
16don MSN
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment
Q4 2025 Management View Frank Bedu-Addo, President, CEO & Director, detailed that "the fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by meaningful advances ...
We are finding opportunities in companies exposed to the building cycle. Admittedly, these companies are mostly exposed to ...
More regulation is needed to address consumer harm arising from SMSFs and the Financial Accountability Regime should apply ...
A three-sport athlete at Princeton High, Bornstein, who is just five-feet tall, plays with an amazing measure of heart and ...
Rates markets are worried about risks to inflation, although central banks will ultimately balance both inflation and ...
In this episode of Investing Compass, Mark and Shani run through the tilts in passive investments and how that exposure impacts investors.
Leading brands, including Walmart, have signed letters of support for unspun's plan to build domestic manufacturing capacity in the U.S. using an AI-enabled 3D weaving technology ...
The Extreme Poverty Eradication Programme was positioned as a radical step by the Pinarayi government. Despite its efficient ...
On 25 March, techUK hosted a session of the Interoperability in Security and Public Safety Forum. The forum brings together ...
More than 54%* of Australians are considering a switch to an electric or hybrid car amid rising fuel costs, but Compare the ...
Star sprinter Animesh Kujur of Odisha won the 100m dash in a photo finish after earlier clinching the 200m title, stealing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results